Defense World
25 Apr 2026, 06:38 UTC · 28w ago
Verdict
Headline takes no side. We score GLMD −0.70 across four claims — strongly bearish.
−0.70strongly bearish
More negative than 89% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Galmed Pharmaceuticals saw short interest surge 2,578.7% to 502,390 shares as of April 15th, representing 11.4% of the company's float.
More negative than 96% of claims this week
Galmed Pharmaceuticals currently holds a consensus analyst rating of 'Sell', reaffirmed by Weiss Ratings.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 88% of claims this week
Galmed Pharmaceuticals shares trade at $0.63 with a market capitalization of just $3.44 million, sitting near a 52-week low of $0.41.
So whatMicro-cap valuation and a stock price hovering near 52-week lows reflect severe financial distress and high risk, severely limiting institutional investment appeal.
More negative than 83% of claims this week
Two Sigma Investments LP bought a new position of 21,200 shares (about 1.28% of the company) valued at approximately $29,000 in the third quarter.
More positive than 43% of claims this week
Which stocks this story touches
More negative than 89% of ticker scores this week
Massive increase in short interest and a consensus 'Sell' rating from analysts.
More negative than 80% of ticker scores this week
The company is experiencing a large growth in short interest.
More negative than 76% of ticker scores this week
The company's shares decreased by 2.3%.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Schaeffers Research
1d ago
−7.8%
Price agrees with the score
$4.63 vs $5.02 close before publication (Apr 24) · not market-adjusted
GLMD chart →
